Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
FP14 - Targeted Therapy - Clinically Focused
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
- Presentations: 16
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP14.03 - Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
00:00 - 00:00 | Presenter: Ji-Youn Han
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 24
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P01.01 - HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
00:00 - 00:00 | Presenter: Pasi A. Janne
- Abstract
Loading...
-
+
P37 - Pathology - Biomarker Testing
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 34
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P37.05 - Prognostic Characteristics and Immunotherapy Response of Non-Squamous NSCLC Patients with KRAS Mutation in East Asian Populations
00:00 - 00:00 | Presenter: Shang-Gin Wu
- Abstract
Loading...
-
+
P86 - Targeted Therapy - Clinically Focused - New Target
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 23
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P86.01 - Phase 1 Study of the AXL Inhibitor DS-1205 in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC
00:00 - 00:00 | Presenter: James Chih-Hsin Yang
- Abstract
Loading... -
+
P86.08 - Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
00:00 - 00:00 | Presenter: Alison M Schram
- Abstract
Loading...
-
+
IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
- Type: Industry Symposium
- Track:
- Presentations: 5
- Coordinates: 1/28/2021, 11:45 - 12:45, Industry Symposia Auditorium (via Industry Hub)
-
+
IS03.04 - ADC Therapies as Targeted Treatment Options in Patients With Advanced NSCLC
12:15 - 12:30 | Presenter: James Chih-Hsin Yang
- Abstract
No abstract available for this presentation
-
+
PL02 - Innovation to Bridge Lung Cancer Care Tomorrow (Japanese, Mandarin, Spanish Translation Available)
- Type: Plenary
- Track: N.A.
- Presentations: 7
- Coordinates: 1/29/2021, 07:00 - 09:00, Scientific Program Auditorium
-
+
PL02.02 - Chair
07:00 - 07:00 | Presenter: James Chih-Hsin Yang
- Abstract
No abstract available for this presentation
-
+
OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
- Type: Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 7
- Coordinates: 1/29/2021, 10:30 - 11:30, Scientific Program Auditorium
-
+
OA03.04 - Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
10:40 - 10:50 | Presenter: Helena Yu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA04 - New Data from Rare EGFR Alterations
- Type: Oral
- Track: Targeted Therapy - Clinically Focused
- Presentations: 8
- Coordinates: 1/29/2021, 11:45 - 12:45, Scientific Program Auditorium
-
+
OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
11:45 - 11:55 | Presenter: Caicun Zhou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
11:55 - 12:05 | Presenter: Joshua K. Sabari
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
- Presentations: 12
- Coordinates: 1/31/2021, 14:15 - 15:15, Scientific Program Auditorium
-
+
MA11.05 - Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
14:25 - 14:30 | Presenter: Paul K. Paik
- Abstract
Loading...
